|
rs7076156
|
|
Crohn Disease
|
|
0.810 |
GeneticVariation
|
BEFREE |
A whole-genome microarray expression study further suggested that the Ala62Thr change in ZNF365 isoform D is related to differential expression of the genes ARL4A, MKKS, RRAGD, SUMF2, TDR1 and ZNF148 in CD.
|
21257989 |
2011 |
|
rs7076156
|
|
Crohn Disease
|
|
0.810 |
GeneticVariation
|
BEFREE |
Collectively, these data support the hypothesis that the non-synonymous Ala62Thr SNP, rs7076156, underlies the association between 10q21 and CD risk and suggest that this SNP acts by altering expression of genes under the control of ZNF365 isoform D.
|
21257989 |
2011 |
|
rs10995190
|
|
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
The objective of this study was to investigate whether the genetic polymorphism rs12665607 of ESR1, rs10995190 of ZNF365, rs3817198 of LSP1 and rs17001868 of SGSM3/MKL1 are associated with the development of breast cancer (BC) in the Chinese women.
|
27432265 |
2017 |
|
rs10995190
|
|
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
The objective of this study was to investigate whether the genetic polymorphism rs12665607 of ESR1, rs10995190 of ZNF365, rs3817198 of LSP1 and rs17001868 of SGSM3/MKL1 are associated with the development of breast cancer (BC) in the Chinese women.
|
27432265 |
2017 |
|
rs10995190
|
|
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
We selected for evaluation 1327 single nucleotide polymorphisms (SNPs) showing the lowest P-values for interaction (P int) in a meta-analysis of genome-wide gene-environment interaction studies with MHT use on risk of breast cancer, 2541 SNPs in candidate genes (AKR1C4, CYP1A1-CYP1A2, CYP1B1, ESR2, PPARG, PRL, SULT1A1-SULT1A2 and TNF) and ten SNPs (AREG-rs10034692, PRDM6-rs186749, ESR1-rs12665607, ZNF365-rs10995190, 8p11.23-rs7816345, LSP1-rs3817198, IGF1-rs703556, 12q24-rs1265507, TMEM184B-rs7289126, and SGSM3-rs17001868) associated with mammographic density in genome-wide studies.
|
26275715 |
2015 |
|
rs10995190
|
|
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
We selected for evaluation 1327 single nucleotide polymorphisms (SNPs) showing the lowest P-values for interaction (P int) in a meta-analysis of genome-wide gene-environment interaction studies with MHT use on risk of breast cancer, 2541 SNPs in candidate genes (AKR1C4, CYP1A1-CYP1A2, CYP1B1, ESR2, PPARG, PRL, SULT1A1-SULT1A2 and TNF) and ten SNPs (AREG-rs10034692, PRDM6-rs186749, ESR1-rs12665607, ZNF365-rs10995190, 8p11.23-rs7816345, LSP1-rs3817198, IGF1-rs703556, 12q24-rs1265507, TMEM184B-rs7289126, and SGSM3-rs17001868) associated with mammographic density in genome-wide studies.
|
26275715 |
2015 |
|
rs10995190
|
|
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
All three measures of mammographic density were associated with breast cancer risk and rs10995190 (p<0.025 for breast cancer risk and p<1 × 10(-6) for rs10995190).
|
25329322 |
2014 |
|
rs10995190
|
|
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
We showed that MIP is associated with a genetic variant known to be associated with mammographic density and breast cancer risk, rs10995190, in a subset of women with genetic data.
|
24722754 |
2014 |
|
rs10995190
|
|
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
We showed that MIP is associated with a genetic variant known to be associated with mammographic density and breast cancer risk, rs10995190, in a subset of women with genetic data.
|
24722754 |
2014 |
|
rs10995190
|
|
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
Associations were also observed with rs10995190 in the ZNF365 gene (P < 1.0 × 10(-6)) and breast cancer risk [HR for the highest vs. lowest quartile, 2.93; 95% confidence interval, 1.73-4.96 and 1.63 (1.10-2.42) for percent and absolute dense volume, respectively].
|
25012995 |
2014 |
|
rs10995190
|
|
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
All three measures of mammographic density were associated with breast cancer risk and rs10995190 (p<0.025 for breast cancer risk and p<1 × 10(-6) for rs10995190).
|
25329322 |
2014 |
|
rs10995190
|
|
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Associations were also observed with rs10995190 in the ZNF365 gene (P < 1.0 × 10(-6)) and breast cancer risk [HR for the highest vs. lowest quartile, 2.93; 95% confidence interval, 1.73-4.96 and 1.63 (1.10-2.42) for percent and absolute dense volume, respectively].
|
25012995 |
2014 |
|
rs10995190
|
|
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
To provide more reliable estimates of the relative risk associated with these loci and investigate possible heterogeneity by subtype of breast cancer, we genotyped the variants rs2380205, rs1011970, rs704010, rs614367, and rs10995190 in 39 studies from the Breast Cancer Association Consortium (BCAC), involving 49,608 cases and 48,772 controls of predominantly European ancestry.
|
22461340 |
2012 |
|
rs10995190
|
|
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
To provide more reliable estimates of the relative risk associated with these loci and investigate possible heterogeneity by subtype of breast cancer, we genotyped the variants rs2380205, rs1011970, rs704010, rs614367, and rs10995190 in 39 studies from the Breast Cancer Association Consortium (BCAC), involving 49,608 cases and 48,772 controls of predominantly European ancestry.
|
22461340 |
2012 |
|
rs10995190
|
|
Breast Carcinoma
|
|
0.770 |
GeneticVariation
|
BEFREE |
Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 × 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049).
|
22348646 |
2012 |
|
rs10995190
|
|
Malignant neoplasm of breast
|
|
0.770 |
GeneticVariation
|
BEFREE |
Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 × 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049).
|
22348646 |
2012 |
|
rs10822013
|
|
Malignant neoplasm of breast
|
|
0.720 |
GeneticVariation
|
BEFREE |
Upon statistical analyses of clinical data from 551 patients and 577 controls, we found that six of the 13 SNPs were associated with breast cancer; namely, rs4973768(Odds ratio (OR) = 1.30, 95% confidence interval (CI) =1.01-1.67), rs981782(OR =1.30, 95% CI=1.01-1.66), rs1432679(OR =0.84, 95% CI=0.70-0.99), rs10759243(OR=1.30, 95%CI=1.09-1.55), rs10822013(OR =1.18, 95% CI=1.00-1.39) and rs704010(OR =1.63, 95% CI=1.04-2.56).
|
27863437 |
2016 |
|
rs10822013
|
|
Breast Carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Upon statistical analyses of clinical data from 551 patients and 577 controls, we found that six of the 13 SNPs were associated with breast cancer; namely, rs4973768(Odds ratio (OR) = 1.30, 95% confidence interval (CI) =1.01-1.67), rs981782(OR =1.30, 95% CI=1.01-1.66), rs1432679(OR =0.84, 95% CI=0.70-0.99), rs10759243(OR=1.30, 95%CI=1.09-1.55), rs10822013(OR =1.18, 95% CI=1.00-1.39) and rs704010(OR =1.63, 95% CI=1.04-2.56).
|
27863437 |
2016 |
|
rs10822013
|
|
Malignant neoplasm of breast
|
|
0.720 |
GeneticVariation
|
BEFREE |
SNP rs10822013 on chromosome 10q21.2, located in the zinc finger protein 365 (ZNF365) gene, showed a consistent association with breast cancer risk in all four stages with a combined per-risk allele odds ratio of 1.10 (95% CI: 1.07-1.14) (P-value for trend = 5.87 × 10(-9)).
|
21908515 |
2011 |
|
rs10822013
|
|
Breast Carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
SNP rs10822013 on chromosome 10q21.2, located in the zinc finger protein 365 (ZNF365) gene, showed a consistent association with breast cancer risk in all four stages with a combined per-risk allele odds ratio of 1.10 (95% CI: 1.07-1.14) (P-value for trend = 5.87 × 10(-9)).
|
21908515 |
2011 |
|
rs10822013
|
|
estrogen receptor-negative breast cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs10822013
|
|
Oestrogen receptor positive breast cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs10995190
|
|
estrogen receptor-negative breast cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 × 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049).
|
22348646 |
2012 |
|
rs16917302
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for BRCA1 mutation carriers [HR, 1.17; 95% confidence interval (CI), 1.07-1.27; P = 7.42 × 10(-4)] and between rs16917302 at ZNF365 (HR, 0.84; 95% CI, 0.73-0.97; P = 0.017) but not rs311499 at 20q13.3 (HR, 1.11; 95% CI, 0.94-1.31; P = 0.22) and breast cancer risk for BRCA2 mutation carriers.
|
22351618 |
2012 |
|
rs16917302
|
|
Oestrogen receptor positive breast cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analyses based on tumor histopathology showed that 19p13 variants were predominantly associated with estrogen receptor (ER)-negative breast cancer for both BRCA1 and BRCA2 mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast cancer for both BRCA1 and BRCA2 mutation carriers.
|
22351618 |
2012 |